Literature DB >> 19819644

Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.

Ji-Youn Sung1, Gou Young Kim, Sung-Jig Lim, Yong-Koo Park, Youn Wha Kim.   

Abstract

Only few studies have evaluated the usefulness of the GLUT1 and p53 status of pancreatobiliary tract carcinomas in revealing tumorigenesis. We studied GLUT1 and p53 immunoexpression in a total of 355 cases of the pancreatobiliary carcinoma to determine the biological significance of GLUT1 and p53 expression. Positive expression of GLUT1 was identified in 38 out of 67 (57.7%) ampulla of Vater (AV) carcinomas, in 27 out of 52 (51.8%) pancreatic (PA) carcinomas, in 38 out of 121 (31.4%) extrahepatic bile duct (EBD) carcinomas, and in 53 out of 115 (46.5%) gallbladder (GB) carcinomas. GLUT1 expression in pancreatobiliary carcinomas showed some positive correlation with histological grade, T stage, N stage, TNM stage, and lymphatic invasion. However, p53 expression showed no correlation with any prognostic factors. In the Kaplan-Meier test, positive GLUT1 expression was a poor prognostic factor in the pancreatobiliary tract cancers; however, only GB cancers were statistically significant (P=0.002). Our results suggest that GLUT1 expression in the AV, EBD, and GB carcinomas is associated with some prognostic factors, and GLUT1 expression is associated with a worse prognosis in the patients with GB carcinomas. Copyright 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819644     DOI: 10.1016/j.prp.2009.07.018

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.

Authors:  Nikolaos Charalampakis; Lianchun Xiao; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Venkatram Planjery; Jane E Rogers; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncology       Date:  2015-09-23       Impact factor: 2.935

2.  ¹⁸F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma.

Authors:  Ran Hong; Sung-Chul Lim
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

3.  Potential role of sugar transporters in cancer and their relationship with anticancer therapy.

Authors:  Moisés Blanco Calvo; Angélica Figueroa; Enrique Grande Pulido; Rosario García Campelo; Luís Antón Aparicio
Journal:  Int J Endocrinol       Date:  2010-07-18       Impact factor: 3.257

4.  GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.

Authors:  Ran Liu; Zheng Fu; Meng Zhao; Xiangqian Gao; Hong Li; Qian Mi; Pengxing Liu; Jinna Yang; Zhi Yao; Qingzhi Gao
Journal:  Oncotarget       Date:  2017-06-13

Review 5.  The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.

Authors:  Min Yu; Han Yongzhi; Shengying Chen; Xiaodan Luo; Ye Lin; Yu Zhou; Haosheng Jin; Baohua Hou; Yanying Deng; Lei Tu; Zhixiang Jian
Journal:  Oncotarget       Date:  2017-06-27

Review 6.  Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis.

Authors:  Ji Wang; Chenyang Ye; Cong Chen; Hanchu Xiong; Binbin Xie; Jichun Zhou; Yongxia Chen; Shu Zheng; Linbo Wang
Journal:  Oncotarget       Date:  2017-03-07

7.  Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients.

Authors:  Gaowa Sharen; Yaojun Peng; Haidong Cheng; Yang Liu; Yonghong Shi; Jian Zhao
Journal:  Oncotarget       Date:  2017-03-21

8.  Correlation Study on the Expression of INSR, IRS-1, and PD-L1 in Nonsmall Cell Lung Cancer.

Authors:  Ma Ting; Yu-E Miao; Feng-Xiu Yu; Guang-Cai Luo; Xin Xu; Li-Xia Xiao; Guo-Qing Zhang; Jin Chang
Journal:  J Oncol       Date:  2022-10-04       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.